Nothing Special   »   [go: up one dir, main page]

PL2968468T3 - Preparaty chimerycznej cytokiny do dostarczania do oka - Google Patents

Preparaty chimerycznej cytokiny do dostarczania do oka

Info

Publication number
PL2968468T3
PL2968468T3 PL14722435T PL14722435T PL2968468T3 PL 2968468 T3 PL2968468 T3 PL 2968468T3 PL 14722435 T PL14722435 T PL 14722435T PL 14722435 T PL14722435 T PL 14722435T PL 2968468 T3 PL2968468 T3 PL 2968468T3
Authority
PL
Poland
Prior art keywords
ocular delivery
chimeric cytokine
cytokine formulations
formulations
chimeric
Prior art date
Application number
PL14722435T
Other languages
English (en)
Inventor
Gregory Zarbis-Papastoitsis
Patricia LOWDEN
Byeong Chang
Original Assignee
Buzzard Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buzzard Pharmaceuticals AB filed Critical Buzzard Pharmaceuticals AB
Publication of PL2968468T3 publication Critical patent/PL2968468T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL14722435T 2013-03-13 2014-03-13 Preparaty chimerycznej cytokiny do dostarczania do oka PL2968468T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779974P 2013-03-13 2013-03-13
PCT/US2014/026416 WO2014160371A1 (en) 2013-03-13 2014-03-13 Chimeric cytokine formulations for ocular delivery
EP14722435.6A EP2968468B1 (en) 2013-03-13 2014-03-13 Chimeric cytokine formulations for ocular delivery

Publications (1)

Publication Number Publication Date
PL2968468T3 true PL2968468T3 (pl) 2021-12-20

Family

ID=50680140

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14722435T PL2968468T3 (pl) 2013-03-13 2014-03-13 Preparaty chimerycznej cytokiny do dostarczania do oka

Country Status (17)

Country Link
US (2) US20140308239A1 (pl)
EP (1) EP2968468B1 (pl)
JP (1) JP6450364B2 (pl)
KR (1) KR102236926B1 (pl)
CN (2) CN107693781B (pl)
AU (2) AU2014243839B2 (pl)
BR (1) BR112015022587A2 (pl)
CA (1) CA2903706C (pl)
DK (1) DK2968468T3 (pl)
ES (1) ES2884813T3 (pl)
HK (1) HK1246692A1 (pl)
IL (1) IL241171A0 (pl)
MX (1) MX2015012404A (pl)
PL (1) PL2968468T3 (pl)
RU (1) RU2015143521A (pl)
SG (2) SG11201507447PA (pl)
WO (1) WO2014160371A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4219538A3 (en) 2010-07-29 2023-08-09 Buzzard Pharmaceuticals AB Receptor binding agents
SG11201507447PA (en) 2013-03-13 2015-10-29 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
TW201538178A (zh) 2014-03-13 2015-10-16 Eleven Biotherapeutics Inc 生產於吹氣成型充塡密封容器內穩定的嵌合型細胞激素蛋白質配方之方法
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
RU2728795C2 (ru) * 2015-04-28 2020-07-31 Свидиш Орфан Биовитрум Аб (Пабл) Композиции, содержащие анакинру
EP3319608A4 (en) * 2015-07-07 2019-04-03 LifeRaft Biosciences, Inc. POLOXAMER 188 FORMULATIONS WITH REDUCED SODIUM AND METHOD OF USE
JP6532959B2 (ja) * 2015-11-30 2019-06-19 ロート製薬株式会社 眼科組成物
EP4008311B1 (en) * 2016-10-12 2023-09-13 PS Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
JP6172880B1 (ja) * 2017-02-01 2017-08-02 協和発酵キリン株式会社 ダルベポエチンを含む液体医薬組成物
EP4153494A4 (en) * 2020-05-21 2024-10-09 Coherus Ophthalmology LLC SYSTEMS AND METHODS FOR PRODUCING STERILE INJECTION DEVICES
WO2022226177A1 (en) * 2021-04-22 2022-10-27 Altavant Sciences Gmbh Compositions of interleukin-1 receptor antagonist
AU2022445159A1 (en) 2022-03-10 2024-09-26 Buzzard Pharmaceuticals AB Inhibitor of interleukin-1 receptor type 1 for use in the treatment of cancer

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188266C (nl) 1975-07-29 1992-05-18 Merck & Co Inc Werkwijze ter bereiding van een oogheelkundig inplantaat.
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
EP0569687B1 (en) 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5998578A (en) 1984-05-18 1999-12-07 New England Medical Center Hospitals, Inc. Biologically active fragments of IL-1β
US5484887A (en) 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
US6107465A (en) 1984-12-21 2000-08-22 Otsuka Pharmaceutical Co., Ltd. IL-1β and derivatives thereof and drugs
DK172052B1 (da) 1984-12-21 1997-09-29 Otsuka Pharma Co Ltd Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
US5122459A (en) 1984-12-31 1992-06-16 Immunex Corporation Gene encoding biologically active human interleukin 1
US4770781A (en) 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2046303C (en) 1989-02-27 2001-05-01 Lee Gehrke Il-1 biological activity inhibitors
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
DK0502956T3 (da) 1989-11-29 1997-10-20 Amgen Boulder Inc Fremstilling af en rekombinant human interleukin-1-inhibitor.
AU7683391A (en) 1990-04-27 1991-11-27 Upjohn Company, The Modified interleukin-1 inhibitors
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU1270592A (en) 1991-02-05 1992-09-07 University Of Maryland Modified interleukin-1beta
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
EP0611302B1 (en) 1991-10-15 2000-03-29 MULLARKEY, Michael F. Receptors for treating late phase inflammatory responses
EP0610336B1 (en) 1991-10-31 2002-03-27 The Victoria University Of Manchester Treatment of neurological conditions by an interleukin-1 inhibiting compound
RU2126262C1 (ru) 1992-09-17 1999-02-20 Амген Боулдер Инк. Фармацевтическая композиция
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
US5340572A (en) 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
WO1995010298A1 (en) 1993-10-12 1995-04-20 Mary Lake Polan Method of contraception
US5861476A (en) 1994-02-02 1999-01-19 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
IT1269989B (it) 1994-09-21 1997-04-16 Dompe Spa Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
JP3269770B2 (ja) 1995-03-02 2002-04-02 参天製薬株式会社 再分散性の優れたイオン性高分子配合水性懸濁点眼剤
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6416753B1 (en) 1996-03-15 2002-07-09 The General Hospital Corporation Method for modulating apoptosis
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
WO1998022130A1 (en) 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye
KR100643058B1 (ko) 1996-12-03 2006-11-13 아브게닉스, 인크. 복수의 Ｖн 및 Ｖк 영역을 함유하는 인간 면역글로불린 유전자좌를 갖는 트랜스제닉 포유동물 및 이로부터 생성된 항체
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
CA2287254A1 (en) 1997-04-21 1998-10-29 Schering Corporation Mammalian cytokines; related reagents and methods
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US7906481B2 (en) 1998-09-25 2011-03-15 Sciaticon Ab Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
MX353234B (es) 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
US6419944B2 (en) 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6471961B1 (en) 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
JP3363832B2 (ja) 1999-05-13 2003-01-08 アルプス電気株式会社 薄膜構造体およびその製造方法
WO2001042304A1 (en) 1999-12-10 2001-06-14 Amgen, Inc. Interleukin-1 receptor antagonist-related molecules and uses thereof
AU782554B2 (en) 1999-12-10 2005-08-11 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
AU778676B2 (en) 1999-12-10 2004-12-16 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US20030007971A1 (en) 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
AU2001236632A1 (en) 2000-02-03 2001-08-14 Regeneration Technologies, Inc. Extraction of growth factors from tissue
US20040026042A1 (en) 2000-04-17 2004-02-12 Edwards Mark Stephen Method and apparatus for making bristle subassemblies
US20020131954A1 (en) 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
EP1282435A2 (en) 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US20030166069A1 (en) 2000-11-28 2003-09-04 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
CA2431600C (en) 2000-12-12 2012-04-17 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
KR20030074790A (ko) 2001-02-06 2003-09-19 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 인터루킨-1 수용체길항제(ｉｌ-1ｒａ)
US20050143333A1 (en) 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
AU2002332931A1 (en) 2001-09-06 2003-03-24 Board Of Regents, The University Of Texas System Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
FR2833268B1 (fr) * 2001-12-12 2005-07-08 Fabre Pierre Dermo Cosmetique Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation
JP2006500905A (ja) 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
US6890654B2 (en) 2002-04-18 2005-05-10 Northwestern University Encapsulation of nanotubes via self-assembled nanostructures
US7029712B1 (en) 2002-07-17 2006-04-18 Biosyntrx Inc Treatment for dry eye syndrome
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US20050033694A1 (en) 2003-06-03 2005-02-10 United States Postal Service. System and method for fleet card management
ATE553747T1 (de) * 2003-06-10 2012-05-15 Lg Life Sciences Ltd Stabile wässrige lösung von human-erythropoietin, die kein serumalbumin enthält
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US20050023872A1 (en) 2003-07-28 2005-02-03 Hetzel Thomas R. Modular seat cushion with interlocking human support and base portions and method of creating and using a seat cushion
CA2543193C (en) 2003-10-27 2015-08-11 Wyeth Removal of high molecular weight aggregates using hydroxyapatite chromatography
KR100543466B1 (ko) 2003-11-13 2006-01-20 삼성전자주식회사 영상 보간 장치 및 방법
ATE554792T1 (de) 2003-12-23 2012-05-15 Pharmacia Corp Stabiles wachstumshormon-flüssigformulierung
US7482323B2 (en) 2004-03-04 2009-01-27 The University Of Tennessee Research Foundation Intracellular interleukin-1 receptor antagonist and uses thereof
US7674464B2 (en) 2004-03-04 2010-03-09 The University Of Tennessee Research Foundation Intracellular interleukin-1 receptor antagonists
LT1729810T (lt) 2004-04-02 2018-11-26 Swedish Orphan Biovitrum Ab (Publ) Il-1ra agregacijos sumažinimo būdas
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
JP5022216B2 (ja) 2004-06-04 2012-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
DK1778723T3 (da) 2004-08-17 2012-12-03 Regeneron Pharma Il-1-antagonistformuleringer
WO2005021578A2 (en) 2004-08-25 2005-03-10 Amprotein Corporation A novel chimeric polypeptide and use thereof
KR20080016780A (ko) 2004-11-24 2008-02-22 테라킨 리미티드 안내 약물 전달용 임플란트
RU2007119989A (ru) 2004-12-02 2009-01-10 Домантис Лимитед (Gb) Композиции, слитые конструкции и конъюгаты plad домена
US7956160B2 (en) 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
EP2322219A3 (en) 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
IL172297A (en) 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for the diagnosis of preeclampsia
US20070248597A1 (en) 2005-10-21 2007-10-25 Henley Charles M Iii Methods of decreasing vascular calcification using IL-1 inhibitors
RU2008144802A (ru) 2006-04-14 2010-05-20 Новартис АГ (CH) Применение антител против ил-1 для лечения глазных расстройств
EP2008100A4 (en) 2006-04-18 2009-12-16 Univ Leland Stanford Junior ESTABLISHING ANTIBODY PROFILES FOR DETERMINING PATIENT SENSITIVITY TO TREATMENT
WO2007145618A1 (en) 2006-06-12 2007-12-21 Therakine Limited Topical treatment for diseases of eye surface
US20080095754A1 (en) 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
US8399421B2 (en) 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
EP2468301A1 (en) 2007-05-29 2012-06-27 Novartis AG New indications for anti-IL-1-beta therapy
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
KR101430584B1 (ko) 2007-07-05 2014-08-14 삼성전자주식회사 이동 통신 시스템에서 심 어플리케이션 툴킷을 제공하는장치 및 방법
AU2008287340A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
JP5894364B2 (ja) 2007-08-16 2016-03-30 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼および付属器組織の炎症を処置するための治療組成物
WO2009048961A1 (en) 2007-10-08 2009-04-16 Anaphore, Inc. Trimeric il-1ra
US9138403B2 (en) * 2007-12-20 2015-09-22 Merck Serono Sa PEG-interferon-beta formulations
WO2009089036A2 (en) 2008-01-09 2009-07-16 Schepens Eye Research Institute Therapeutic compositions for treatment of ocular inflammatory disorders
CN101969929B (zh) * 2008-01-15 2014-07-30 Abbvie德国有限责任两合公司 粉末状蛋白质组合物及其制备方法
BRPI0918978A2 (pt) * 2008-09-10 2015-12-01 Genentech Inc composições e métodos a prevenção da degradação oxidativa das proteínas
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
RU2011126338A (ru) 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
AU2010203425B2 (en) 2009-01-09 2015-04-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of corneal disorders
US20120014970A1 (en) 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
BRPI1008602A8 (pt) 2009-02-18 2018-01-02 Eyeon Particle Sciences Llc uso de co-polímero bi-funcional para as aplicações oftálmicas e outras aplicações tópicas e locais
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
CA2726232A1 (en) 2009-07-16 2010-08-12 Arecor Limited Stable formulation of a therapeutic protein
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
US20130064788A1 (en) 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
WO2011063195A2 (en) 2009-11-20 2011-05-26 Dr. Reddy's Laboratories Ltd. Purification of modified cytokines
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
EP4450523A2 (en) 2010-04-02 2024-10-23 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
US20130195868A1 (en) 2010-06-24 2013-08-01 Eleven Biotherapeutics, Inc. Treating surface of the eye disorders
EP4219538A3 (en) 2010-07-29 2023-08-09 Buzzard Pharmaceuticals AB Receptor binding agents
JP2013543862A (ja) * 2010-11-08 2013-12-09 ヒールオア・リミテッド 眼科用緩衝組成物およびその使用方法
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
US9359405B2 (en) 2011-03-14 2016-06-07 Phlogo Aps Antagonists of the interleukin-1 receptor
CA2843197A1 (en) * 2011-07-29 2013-02-07 Eleven Biotherapeutics, Inc. Purified proteins
SG11201507447PA (en) 2013-03-13 2015-10-29 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery

Also Published As

Publication number Publication date
CN107693781A (zh) 2018-02-16
DK2968468T3 (en) 2021-07-26
IL241171A0 (en) 2015-11-30
BR112015022587A2 (pt) 2017-10-24
AU2018282269B2 (en) 2020-06-11
AU2014243839A1 (en) 2015-09-17
JP2016521252A (ja) 2016-07-21
US10799589B2 (en) 2020-10-13
RU2015143521A (ru) 2017-04-19
EP2968468A1 (en) 2016-01-20
HK1246692A1 (zh) 2018-09-14
SG11201507447PA (en) 2015-10-29
WO2014160371A1 (en) 2014-10-02
CN107693781B (zh) 2021-11-09
CA2903706C (en) 2024-01-23
JP6450364B2 (ja) 2019-01-09
KR102236926B1 (ko) 2021-04-06
AU2018282269A1 (en) 2019-01-17
KR20150126688A (ko) 2015-11-12
RU2015143521A3 (pl) 2018-03-22
SG10201707477SA (en) 2017-10-30
ES2884813T3 (es) 2021-12-13
US20180177877A1 (en) 2018-06-28
US20140308239A1 (en) 2014-10-16
CA2903706A1 (en) 2014-10-02
EP2968468B1 (en) 2021-07-14
AU2014243839B2 (en) 2019-01-03
CN105392494A (zh) 2016-03-09
MX2015012404A (es) 2016-02-03

Similar Documents

Publication Publication Date Title
HK1246692A1 (zh) 用於眼部遞送的嵌合細胞因子製劑
IL246025A0 (en) Formulations for neoplasia compounds
GB201319791D0 (en) Formulations
HK1220617A1 (zh) 因子 多肽調配物
EP2970924A4 (en) PHYTASEFORMULIERUNG
GB201308917D0 (en) Delivery
GB201319792D0 (en) Formulations
IL241109A0 (en) Targeted vaccines for veterinary use
HK1224228A1 (zh) 新型製劑
HK1214951A1 (zh) 眼用製劑
SG11201509194SA (en) Radiomitigating pharmaceutical formulations
HK1213273A1 (zh) 重組因子 製劑
ZA201602718B (en) Formulation for gonadotropins
HK1214531A1 (zh) 穩定的靜脈內製劑
PL2815740T3 (pl) Preparat oftalmologiczny
GB2520410B (en) Digital applanation tonometer
GB201308035D0 (en) Delivery
GB201306262D0 (en) Controlled delivery watering can